Nanexa - kommende stor aftale med novo?
-
Nanexa: Highlights den kommende uge
16/6-19:6 Deltagelse Bio International Convention
20/6-23/6: Late breaking Abstract poster presentation. ADA Congress (American Diabetes Association) https://professional.diabetes.org/scientific-sessions
Samt yderligere formidling JournalDiabetes website formentlig under "Ahead of Print" i forbindelse med eller efter kongressen. https://diabetesjournals.org/diabetes
-
Det lader til at skride planmæssigt frem mod en aftale; PharmaShell udvalgt som en af de 3 bedste teknologier på BIO 2025 og CEO'en virker i videoen til at være i fortrinligt humør, før data præsenteres på ADA kongressen denne søndag kl. 19:30.
The team at Nanexa AB have thoroughly enjoyed our time at this year's BIO International Convention in Boston.
We've had many fantastic, fruitful conversations with new, old and potential PharmaShell partners, and have also had the time to present precisely how it works in the context of our NEX-22 asset, a formulation of liraglutide which we believe will bring lasting and thus improved effects to diabetes patients.
As the event wraps up, we are gearing up for our second conference of the week, and will soon be on our way to this year's American Diabetes Association event in Chicago.
We would also like to give a special thanks to MJH Life Sciences' Chris Spivey, who named PharmaShell as one of his top 3 technologies on display at BIO. Watch the full video interview with our CEO, David Westberg, here: https://lnkd.in/gGsmmmfF
-
Poster fra ADA uploadet af Nanexa
-
Prøver med billede
-
Nanexa Signs Continuation of Feasibility Agreement with Major Pharmaceuticals Company to Investigate PharmaShell
Long-Acting Formulations in a Multi-Billion USD Market -
Der indikeres stadig aftaler i 2025. Ovenstående feasibility aftale (ikke NN) angives til et ca. 3 mia USD produkt. Forhandlinger med NN lader til at kunne bekræftes i kraft af Nanexa er forpligtet til at kommunikere ophør. Lyt selv og vurder i 2 kvartal interview. https://www.youtube.com/watch?v=w5Vbi_qcQ6w
-
Tinyreply har på Reddit lavet en fin opsamling Nanexa's nuværende situation september 2025. Der ser ret interesant ud. Umiddelbart synes Nanexa at have kvaliteter som konkurrenterne ikke kan matche. Jeg har lagt min kommentar øverst i feltet da der ikke længere er ret meget aktivitet i tråden. https://www.reddit.com/r/aktietips/comments/1ngsxpc/står_nanexa_foran_et_gennembrud/
-
Pfizer på vej til at købe Metsera for at få fingrene i deres Long Acting Injectable og få en vej ind i fedmemarkedet.
https://finance.yahoo.com/news/pfizer-closes-7-3-billion-040417987.html -
API mængder. Bemærk fra Metsera præsentation. På flere fora diskuteres API mængder bl.a. som havende stor betydning for produktions omkostninger.
-
Screendump fra Discord Nanexa forum. Oprindelig fra Metsera presentation.
-
Nanexa har opdateret clinical trials til COMPLETED 22/9
https://clinicaltrials.gov/study/NCT06439056?OR=OfficeMobile&tab=history
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind